<DOC>
	<DOCNO>NCT01297777</DOCNO>
	<brief_summary>The aim study evaluate efficacy term clinical biological response rate Imatinib Mesylate therapy patient systemic mastocytosis lack KIT mutation .</brief_summary>
	<brief_title>Imatinib KIT-negative Systemic Mastocytosis</brief_title>
	<detailed_description>In vitro study prove imatinib inhibits wild type Kit ( wtKit ) suppress proliferation HMC-1V560G cell line , ineffective inhibit growth HMC-1V560G , D816V cell . Apart wtKit , Kit molecules carry mutation extracellular , transmembrane juxtamembrane domain , V560G , F522C K509I , remain sensitive imatinib . In contrast , several experiment provide compelling evidence regard resistance growth-inhibitory effect imatinib cell carry D816V KIT mutation . As consequence , sensitive specific method use order avoid `` false '' KIT mutation-negative case , purpose , mainly case low bone marrow mast cell number , mutational study perform use highly purify bone marrow mast cell mean Facs sort system well whole bone marrow , unsorted mononuclear cell fraction mononuclear cell fraction pre-enriched use magnetic bead conjugate anti-CD25 monoclonal antibody . In present study mutational study perform case purify bone marrow mast cell ( purity &gt; 97 % ) use FACSaria system ( Becton-Dickinson Biosciences ) previously describe . Patients without B C finding accord World Health Organization , without feature biological progression disease receive oral Imatinib Mesylate 300 mg daily 12 month clinical progression/unacceptable toxicity . Patients B C finding biological progression initially receive oral Imatinib Mesylate 300 mg daily two week ; , dose increase 400 mg/day except patient develop hematological dose-limiting toxicity . Biological progression define presence least one follow feature : ) increase serum tryptase level &gt; 200 ng/mL , ii ) diffuse bone sclerosis , iii ) patchy sclerosis osteolysis increase risk bone fracture significant bone pain , , iv ) organomegalies lymph node enlargement due mastocytosis .</detailed_description>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Age old 18 year . Diagnosis systemic mastocytosis absence ckit mutation . ECOG ≤ 3 . Signed informed consent . Previous therapy tyrosin kinase inhibitor . Positive antibody HIV active viral hepatitis . Impaired liver function ( total bilirubin ≥ 2.0 mg/dl , AST ALT &gt; 3 x upper limit normal ) . Impaired renal function ( ≥ 2.0 mg/dL ) . Grade IIIIV cytopenia relate mastocytosis . Severe cardiopathy ( grade III/IV NYHA , leave ventricular ejection fraction &lt; 50 % ) . Pregnancy breastfeed . Female patient use contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mast cell</keyword>
	<keyword>Mastocytosis</keyword>
	<keyword>Mast cell disease</keyword>
</DOC>